Eledon Pharmaceuticals, Inc. (ELDN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELDN Stock Price Chart Interactive Chart >
ELDN Price/Volume Stats
|Current price||$3.57||52-week high||$9.90|
|Prev. close||$3.65||52-week low||$2.27|
|Day high||$3.75||Avg. volume||59,453|
|50-day MA||$3.23||Dividend yield||N/A|
|200-day MA||$4.65||Market Cap||49.11M|
Eledon Pharmaceuticals, Inc. (ELDN) Company Bio
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Most Popular Stories View All
ELDN Latest News Stream
|Loading, please wait...|
ELDN Latest Social Stream
View Full ELDN Social Stream
Latest ELDN News From Around the Web
Below are the latest news stories about Eledon Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELDN as an investment opportunity.
Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead asset AT-1501 Catalyst-rich period ahead with four clinical trial readouts anticipated in 2022 Well capitalized with sufficient cash to fund operations into 2024 IRVINE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage bio
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Confere
For investors seeking the strongest possible returns, there has always been a clear path. It involves risk, but the rewards are real. We’re talking, of course, about the outsized gains available in penny stocks, the low-priced equities that can slide under the radar. Historically, these are shares that sold for less than an old English shilling – just pennies. Later, they were defined as stocks selling for less than a one dollar per share; today, they’re the shares priced at less than $5. No mat
IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that members of management will be participating in two upcoming virtual investor conferences: Event:LifeSci Partners Corporate Access Event (January 5-7, 2022)F
A number of insiders bought Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock last year, which is great news for shareholders
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
ELDN Price Returns